Yumanity Therapeutics Operating Income

Yumanity Therapeutics (YMTX) currently reports a operating income of $-6.9M as of March 2025. That compares with $-16M in the prior-year period — up 55.7% year over year. Use the charts on this page to explore Yumanity Therapeutics's operating income history and peer comparisons.

Yumanity Therapeutics's operating income increased from $-16M to $-6.9M — a 55.7% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Yumanity Therapeutics reported $-6.9M in operating income as of March 2025. That compares with $-16M in the prior-year period — up 55.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-6.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Yumanity Therapeutics, and consider following YMTX for alerts when major investors trade the stock.

Yumanity Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-6.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YMTX with unrelated industries.